Micro-scale analysis of mesenchymal to epithelial transition in lung cancer. The mesenchymal to epithelial transition (MET) is the counterpart to the epithelial to mesenchymal transition (EMT). During embryogenesis, this bidirectional change of cell state allows differentiated epithelial cells to take on stem-like mesenchymal properties (EMT), detach from their basement membrane, migrate, attach and form new epithelial structures (MET). The EMT process has been shown to be generalizable and involved in many aspects of organogenesis. Although MET is equally important, there is currently little direct experimental evidence. The inherent plasticity of epithelial cells to undergo a mesenchymal transition explains several key features of the invasive and metastatic phenotypes in epithelial cancers. By activating this pathway, epithelial cells in the early phases of neoplastic transformation could detach, gain motility and change their transcriptome in ways that favor invasion. Upon reaching a hospitable niche, such neoplastic cells could revert, wholly or in part, to an epithelial state through MET. The present proposal will use a novel methodology integrating flow cytometric cell sorting, microprinting, microculture and microscopic imaging to directly demonstrate MET for the first time in unpassaged samples from non-small cell lung cancer patients. This technology will allow complex experiments to be performed using cells from primary samples where cells of interest are rare, or the sample itself is limiting. In the firt Aim, we propose to identify cytokines and other factors capable of driving MET using sort-purified unpassaged non-small cell lung cancer cell subsets in an in vitro microculture system.
The second Aim will address the potential effects of sort-purified vascular endothelial cells, pericytes and mesenchymal stromal cells on MET.

Public Health Relevance

This project is directed toward an understanding of the mesenchymal to epithelial transition (MET) in non- small cell lung cancer. MET is the lesser studied part of the process by which epithelial cancer cells are believed to transition to a mesenchymal phenotype, disseminate and seed metastatic lesions. The proposed study will be performed using unpassaged sort-purified clinical samples and the soluble and cellular factors driving MET will be identified using a novel micro-scale cell culture system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA191647-01
Application #
8813680
Study Section
Special Emphasis Panel (ZCA1-TCRB-5 (O2))
Program Officer
Ault, Grace S
Project Start
2014-12-01
Project End
2016-11-30
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$181,024
Indirect Cost
$45,813
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Donnenberg, Vera S; Zhang, Jayce Jieming; Moravcikova, Erika et al. (2018) Antibody-based cell-surface proteome profiling of metastatic breast cancer primary explants and cell lines. Cytometry A :
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904
Moravcikova, Erika; Krepela, Evzen; Donnenberg, Vera S et al. (2017) BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma. Int J Cancer 141:2050-2061
Mehta, Kunal; Moravcikova, Erika; McFall, David et al. (2017) The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer. Ann Thorac Surg 104:321-328
Donnenberg, Vera S; Donnenberg, Albert D (2015) Coping with artifact in the analysis of flow cytometric data. Methods 82:3-11